Digital Commons Network^™

How To Respond To Racist Patients: Recommendations From A Literature Review, Benjamin Caplan Ba (4th Year Medical Student), Jocelyn Mitchell-Williams Md, Phd

Cooper Rowan Medical Journal

Introduction: Dealing with racist patients is not uncommon, and these interactions can sever the therapeutic alliance, as well as leave providers feeling isolated, dehumanized, and ashamed. Investigation of published recommendations for handling these situations can give victims, peers, and institutions the tools necessary to prepare, protect, and support providers through these challenging encounters.

Methods: This paper is a literature review. For inclusion in this review, studies must have met the criteria of providing recommendations for healthcare providers or institutions on how to deal with racist patients. Excluded articles did not include recommendations on how to handle such situations or did …

Effective Dose Of Intravenous Oxycodone Depending On Sex And Age For Attenuation Ofintubation-Related Hemodynamic Responses, Keum Young So, Ki Tae Jung, Bo Hyun Jang, Sang Hun Kim

Turkish Journal of Medical Sciences

Background/aim: Preoperative intravenous oxycodone may help to prevent or attenuate intubation-related hemodynamic responses (IRHRs), but its pharmacokinetics differs according to age and sex. Therefore, we investigated the 95% effective dose (ED95) of intravenous oxycodone for attenuating all IRHRs, depending on the age and sex of the study population. Materials and methods: All patients were allocated to one of 6 groups: 1) 20-40 year old males, 2) 41-65yearold males, 3) 66-80 year old males, 4) 20-40 year old females, 5) 41-65yearold females, and 6) 66-80 year old females (groups YM, OM, EM, YF, OF, and EF, respectively). Using Dixon's up-and-down method, …

Guest Editor’S Note

Comparative Civilizations Review

No abstract provided.

Nevirapine Hepatotoxicity: Case Report And Discussion, Matt Baichi

The Medicine Forum

Nevirapine (viramune) is a nonnucleoside reverse transcriptase inhibitor commonly used in combination with other antiretroviral medicines in the treatment of HIV/AIDS. The safety profile of nevirapine, as determined by review of prospective clinical trials, reports rash with an incidence of 16% as the most common side effect. Clinical hepatitis is reported to occur with an incidence of 1%. A review of the literature shows many case reports of nevirapine-induced hepatotoxicity in patients receiving both treatment and prophylaxis for HIV. The purpose of this case report is to stress the importance of early recognition and withdrawal of the offending drug.